Postponement of the publication of Predilife's 2024 annual results

Predilife, a company specializing in pathological risk prediction, has announced the postponement of the publication of its 2024 annual results. Initially scheduled for April 30, 2025, this publication is now expected on May 15, 2025, after the market closes. The annual financial report is scheduled to be released no later than May 30, 2025.

This delay is caused by the spin-off of MammoRisk, a major transaction that requires additional consolidation and accounting work. This situation therefore requires an extended period of time to finalize audit procedures.